Subscriber access provided by READING UNIV
Article
Alpha-linolenic acid from Perilla frutescens var. japonica oil protects A#-induced cognitive impairment through regulation of APP processing and A# degradation Ah Young Lee, Myoung Hee Lee, Sanghyun Lee, and Eun Ju Cho J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b03941 • Publication Date (Web): 02 Nov 2017 Downloaded from http://pubs.acs.org on November 2, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 60
Journal of Agricultural and Food Chemistry
1
Alpha-linolenic acid from Perilla frutescens var. japonica oil protects Aβ-
2
induced cognitive impairment through regulation of APP processing and
3
Aβ degradation
4
Ah Young Lee1, Myoung Hee Lee2, Sanghyun Lee3, Eun Ju Cho1,*
5
1
6
University, Busan 46241, Republic of Korea
7
2
8
Development Administration, Gyeongnam 50424, Republic of Korea.
9
3
10
Department of Food Science and Nutrition & Kimchi Research Institute, Pusan National
Department of Southern Area Crop Science, National Institute of Crop Science, Rural
Department of Integrative Plant Science, Chung-Ang University, Gyeonggi 17546, Republic
of Korea.
11 12 13 14 15 16 17 18 19 20 21
Corresponding authors: Eun Ju Cho, Department of Food Science and Nutrition, Pusan
22
National University, Busan 46241, Republic of Korea. Tel: +82-51-510-2837, Fax: +82-51-
23
583-3648. E-mail address:
[email protected] (E. J. Cho). 1
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
24
ABSTRACT
25
Alzheimer’s disease (AD) is characterized by progressive cognitive and memory impairment.
26
The major pathological hallmark of AD is the accumulation of amyloid beta (Aβ), which is
27
produced from the amyloid precursor protein (APP) through cleavage of β- and γ-secretase.
28
Recently, dietary plant oil containing ω-3 polyunsaturated fatty acid has become attractive
29
alternative sources to fish oil containing eicosapentaenoic acid or docosahexaenoic acid
30
(DHA). We investigated whether ALA isolated from perilla oil has direct effects on
31
improvement of cognitive ability and molecular mechanisms in APP processing in
32
comparison with DHA. In the present study, ICR mice were treated orally with ALA or DHA
33
(100 mg/kg/day) for 14 days after i.c.v. injection of Aβ25-35. Administration of ALA resulted
34
in a prevention of learning and memory deficit in Aβ25-35-injected mice compared with the
35
control group, observed in T-maze, novel object recognition and Morris water maze tests.
36
ALA supplementation also markedly ameliorated the Aβ25-35-induced oxidative stress by
37
inhibition of lipid peroxidation and nitric oxide overproduction in the mouse brain, liver and
38
kidney, almost down to the levels in DHA-administered group. These effects of ALA on
39
protective mechanisms were related to the regulation of APP processing via promoting non-
40
amyloidogenic pathway such as up-regulation of soluble APP alpha, C-terminal fragment
41
alpha/beta ratio and A disintegrin and metalloprotease10 protein expressions. Furthermore,
42
ALA inhibited the amyloidogenic pathway through the down-regulation of β-site APP-
43
cleaving enzyme and presenilin2. ALA also enhanced Aβ degradation enzyme, insulin
44
degrading enzyme. In conclusion, the present study indicated beneficial effect of ALA in
45
improving the cognitive ability against Aβ25-35, and these effects were comparable to those
46
exerted by DHA. Its neuroprotective effects are mediated, in part, by regulation of APP
2
ACS Paragon Plus Environment
Page 2 of 60
Page 3 of 60
Journal of Agricultural and Food Chemistry
47
processing and Aβ degradation, thus ALA might be a potential candidate for prevention or
48
treatment of neurodegenerative diseases such as AD.
49
KEY WORDS: alpha-linolenic acid, Aβ25-35, Alzheimer’s disease, cognitive ability, perilla
50
frutescens
3
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
51
INTRODUCTION
52
Accumulation of amyloid beta (Aβ), which is a neuropathological hallmark of Alzheimer’s
53
disease (AD), correlates with cognitive dysfunction.1 Many studies indicated that Aβ plaques
54
are accompanied by neurotoxicity and oxidative stress, which generates free radicals with
55
lipid peroxidation in the brain.2-6 Amyloid precursor protein (APP) is cleaved by two
56
pathways; amyloidogenic and non-amyloidogenic pathways. In the amyloidogenic pathway,
57
cleavage by β- and γ-secretase initiates the production of neurotoxic Aβ.7 First, APP is
58
cleaved by the β-secretase, also known as β-site APP cleaving enzyme (BACE) and produces
59
a transmembrane C-terminal fragment β (CTFβ). CTFβ is then cleaved by γ-secretase, which
60
is comprised of four membrane proteins, presenilin1 (PS1), PS2, nicastrin and anterior
61
pharynx defective 1.8 On the other hand, the non-amyloidogenic pathway involves α-
62
secretase, which cleaves APP to produce non-toxic soluble neurotrophic fragment (sAPPα)
63
and CTFα, resulting in decrease the Aβ secretion. A disintegrin and metalloprotease 10
64
(ADAM 10), a key protease of α-secretase, has been shown prevention of the excessive Aβ
65
accumulation in AD mouse model.9 In the brain, clearance of Aβ involves enzymatic
66
degradation by insulin-degrading enzyme (IDE) and neprilysin (NEP).10 In addition, Aβ
67
transportation across the blood-brain barrier (BBB) from brain mediated by receptor for
68
advanced glycation end products (RAGE) and low-density lipoprotein receptor-related
69
protein 1 (LRP-1).11 Therefore, APP processing by α-secretase and regulation of Aβ
70
metabolism has been suggested as a potential therapeutic target for AD. Acetylcholinesterase
71
inhibitors such as donepezil, rivastigmine and galantamine were used for the symptomatic
72
treatment of mild-to-moderate AD patients. However, they have shown limited impact on the
73
clinical course of AD, or side effects such as gastrointestinal disturbances or tolerability.12,13
4
ACS Paragon Plus Environment
Page 4 of 60
Page 5 of 60
Journal of Agricultural and Food Chemistry
74
Several studies demonstrated that plant-derived epigallocatechin gallate, luteolin and
75
ginsenoside Rg1 promote the non-amyloidogenic α-secretase activity pathway and reduce the
76
generation of Aβ.14-17 Moreover, Grimm et al.18,19 reported that lipids including phospholipids,
77
gangliosides and cholesterols exhibit anti-amyloidogenic properties. A number of clinical
78
trials targeting the non-amyloidogenic pathway are currently ongoing for application in
79
AD.20-22 To date, however, there are no effective therapeutic agents for AD.
80
Recently, dietary lipids are major concern in health care. It has been focused not only on the
81
amount of dietary lipids but also on the types of fatty acids in the diet.23-25 In general, it was
82
recommended that intake of monounsaturated- or polyunsaturated-fatty acids rather than
83
saturated fatty acids could reduce the risk of degenerative disease such as cardiovascular
84
disease. In particular, there is strong supporting evidences that ω-3 polyunsaturated fatty acid,
85
lead to lower risk of certain chronic diseases such as heart disease, arthritis and
86
inflammation.26-28 The beneficial effect of ω-3 fatty acid on human health is well established,
87
and there is relationship between ω-3 fatty acid uptake and prevention of AD or cognitive
88
decline.29-33 In contrast, eicosapentaenoic acid and docosahexaenoic acid (DHA) derived
89
from marine products are both associated with toxicological and hormonal effects stimulated
90
by environmental contamination such as methyl mercury poisoning. Therefore, the plant-
91
derived ω-3 fatty acid, alpha-linolenic acid (ALA), is considered as the best alternative
92
source.34 Previous studies showed that consumption of dietary ALA reduced the risk of
93
cardiovascular disease35 and stroke.36 In addition, Gao et al.37 demonstrated that long-term
94
dietary intake of ALA improved the cognitive function through the activation of extracellular
95
signal-regulated kinases (ERK) and Akt signaling in aged-rat model. However, the direct
5
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
96
effects of ALA on Aβ-injected AD model and its mechanisms have not been completely
97
understood yet.
98
We recently reported that supplementation of Perilla frutescens var. japonica oil, which
99
contains the highest proportion of ALA among the vegetable oils, ameliorated Aβ-induced
100
cognitive deficits evidenced by increased recognition ability and the levels of brain-derived
101
neurotrophic factor protein expression, as well as suppressed the inflammatory-related
102
protein expressions, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2
103
(COX-2).38 We speculated that ALA from perilla oil may contribute to prevention of Aβ
104
neurotoxicity in the brain. There are extensive literatures on the effect of DHA on human
105
health, especially in relation to brain development and function.39-42 DHA can be obtained
106
from diet, and is commonly found in fish oil or synthesized from ALA in the body. However,
107
most studies so far have been shown to limited conversion efficiency of ALA to DHA,43-46
108
suggesting that these ω-3 fatty acids that are derived from different sources (plant or marine)
109
might have their own comparable specific effects on cognitive improvement. Therefore, this
110
study was designed to investigate the direct effect of ALA in comparison with DHA, on the
111
cognitive decline induced by Aβ and the associated molecular mechanisms involved in APP
112
processing and Aβ metabolism.
113
114
MATERIALS AND METHODS
115
Sample Preparation
116
P. frutescens was kindly supported by the Southern Area Crop Science, Rural Development
117
Administration, Republic of Korea. Perilla oil was treated with urea with cooling, and large 6
ACS Paragon Plus Environment
Page 6 of 60
Page 7 of 60
Journal of Agricultural and Food Chemistry
118
amount of ALA was isolated after gas chromatography-flame ionization detector analysis.47
119
DHA ethyl ester was used as a positive control, and was purchased from Cayman Chemical
120
(Ann Arbor, MI, USA).
121 122
Animals and experimental protocols
123
Male ICR mice (5-weeks-old) weighing between 25 to 27 g were supplied from Orient Inc.
124
(Seongnam, Korea). Experimental mice were bred in 4 or 5 per plastic cages in a controlled
125
room (temperature, 20 ± 2°C; humidity, 50 ± 10%; 12 h light/dark cycle), and they were
126
provided with normal pellet diets and water. Mice were assigned into four groups (n = 6 per
127
group) as follows: Normal group = i.c.v. injection of 0.9% NaCl (Bio Basics Inc., Markham,
128
Ontario, Canada) + oral administration of water; Control group = i.c.v. injection of Aβ25-35 +
129
oral administration of water; ALA group = i.c.v. injection of Aβ25-35 + oral administration of
130
alpha-linolenic acid (100 mg/kg/day); DHA group = i.c.v. injection of Aβ25-35 + oral
131
administration of docosahexaenoic acid (100 mg/kg/days) for 14 days using a sonde gavage.
132
No significant differences in the initial body weights among the groups were observed (Table
133
1).
134 135
Aβ25-35-infused mouse model
136
To induce aggregation, Aβ25-35 peptide (Sigma Aldrich Co., St. Louis, MO, USA) was
137
dissolved in distilled water, and then incubated for 3 days at 37°C.48 The aggregated Aβ25-35
138
solution was injected intracerebroventricularly in accordance with method of Laursen and
139
Belknap.49 Each mice were lightly anesthetized with zoletil (Virbac Korea, Seoul, Korea) and
140
rompun (Bayer Korea, Seoul, Korea). Briefly, 5 µL of 0.9% NaCl or 5 nmol of Aβ25-35 7
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
141
aggregate solution was injected using a in 0.8 mm posterior and 1.5 mm lateral from the
142
bregma with depth of 2.2 mm beneath the surface of the brain at a rate of 1 µL/min using a 10
143
µL Hamilton microsyringe with 26-gauge stainless-steel needle, which was left with 1 min
144
waiting-period in the injection site before removal. All animal experimental procedures were
145
approved by the Pusan National University Institutional Animal Core and Use Committee
146
(Approval Number: PNU-2015-0888). The behavioral tests started on day 11 after injection at
147
the same time, and were performed in accordance with the experimental schedules as shown
148
in Figure 1.
149 150
T-maze test
151
T-maze test was carried out following the previous reports, which was established by
152
Montgomery.50 It consisted of a start box, left and right arms with a door to block the left
153
arms. T-maze were constructed using black boards (stems = 50 cm, width = 13 cm, height =
154
20 cm). During the training session, the left arm of T-maze was blocked. Each mouse was
155
placed at the start box and allowed to explore only the right arm. The number of
156
explorations on the right arm of T-maze during 10 min-period was measured. 24 h after the
157
training session, the door was removed. They were allowed to freely explore both the right
158
and left arms for 10 min and the number of the exploring in each arm was recorded. The
159
percentage of space perceptive ability (%) was expressed as a ratio of the number of entries
160
either right arm (old route) or left arm (new route) to the number of total arms entries.
161 162
Novel object recognition test
8
ACS Paragon Plus Environment
Page 8 of 60
Page 9 of 60
Journal of Agricultural and Food Chemistry
163
The novel object recognition test was performed using square-shaped black box (each 40 ×
164
30 × 20 cm).51 In the training session, two identical objects (A and A’, plastic bottles) were
165
fixed symmetrically at floor of the field. Mouse was placed at squire box for 10 min and the
166
number of touches each objects was recorded. After that, the mouse was returned to home
167
cage. 24 h after training session, one of the objects was replaced by a new object (B, another
168
plastic bottle), which is different shape but in similar size and color. Mouse were located into
169
the same field and was allowed to explore familiar object or novel object freely for 10 min.
170
The number of touches each objects was measured. The percentage of object perceptive
171
ability (%) was expressed a ratio by following equation; [A/(A+A’) X 100 in the training
172
session, and B/(A+B) X 100 in the test session].
173 174
Morris water maze test
175
The spatial and long-term memory of mice was conducted by the method of Morris.52
176
Experimental apparatus consisted of a dark plastic circular pool (diameter = 80 cm, height =
177
40 cm) filled with water (22 ± 1°C), and equally divided into four quadrants. Water was made
178
opaque by addition with white non-toxic poster color, thereby the platform was invisible. A
179
platform (diameter = 8 cm) was placed in the midpoint of one quadrant submerged 1 cm
180
beneath the surface of water. Visual cues were presented on the walls of the apparatus for
181
navigation. In the training session, each mouse was placed into water pool and allowed to
182
swim (maximum 60 s) to find the hidden platform, three trials per day for consecutive 3 days.
183
When the mouse that found the hidden platform, it is allowed to stay on the platform for 15 s.
184
If the mouse failed to find the hidden platform within 60 s, they were guided to platform and
185
allowed to stay there for 15 s to help them remember the platform location. After completion
9
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
186
of training trial for 3 days, in the primary test of probe trial, the experiment was performed as
187
before. The latency time required to reach the hidden platform was recorded. Next, the
188
platform was removed and each mouse was allowed to swim freely for 60 s. Then the
189
frequency of mice crossing over the target quadrant and the time that mice spent swimming
190
in the target quadrant where the platform was previously located was measured. In the tertiary
191
test, the water was made transparent and the latency time to reach the visible platform, which
192
was positioned 1 cm above the water surface, was recorded.
193 194
Measurement of lipid peroxidation
195
The levels of MDA were measured according to previous method.53 After completion of
196
behavioral tests, mice were sacrificed under anesthesia with zoletil and rompun. Afterwards,
197
the brain, liver, and kidneys of mice were collected immediately and dissected tissues were
198
on the ice. Tissues homogenate was prepared, and the supernatant was collected following
199
centrifugation at 3000 rpm for 15 min at 4°C. The samples were added to 1% phosphoric acid
200
(Samchun Pure Chemical Co., Gyeonggi, Pyeongtaek, Korea) and 0.67% thiobarbituric acid
201
(TBA, Lancaster Synthesis, Ward Hill, MA, USA). solution. After boiling at 95°C for 45 min,
202
the mixture was cooled in an ice, and 2 mL of 1-butanol (Samchun Pure Chemical Co.) were
203
mixed followed by centrifugation at 3,000 rpm for 10 min. The resulting color was detected
204
using microplate absorbance reader at 535 and 520 nm. Lipid peroxide levels were expressed
205
in terms of MDA equivalents using standard curve.
206 207 208
Nitric oxide (NO) scavenging activity NO concentration in brain, liver and kidney was examined by the method of Schmidt et al.54
10
ACS Paragon Plus Environment
Page 10 of 60
Page 11 of 60
Journal of Agricultural and Food Chemistry
209
A supernatant of homogenized tissue was mixed with distilled water, and then dilution was
210
added to the same amount of Griess reagent (Sigma Aldrich Co.). After incubation in 37°C for
211
30 min, the absorbance of each solution was measured using microplate reader at 540 nm.
212
The NO levels were calculated based on the NaNO2 (Junsei Chemical Co., Tokyo, Japan)
213
standard curve.
214 215
Western blotting
216
The mice brains were rapidly removed and homogenized with lysis buffer containing a
217
protease inhibitor cocktail. The homogenates were centrifuged at 13,000 rpm for 30 min. The
218
protein concentrations were determined in the collected supernatants. Equal amounts of
219
proteins were resolved on 10-13% sodium dodecyl sulfate polyacrylamide gel electrophoresis
220
(SDS-PAGE). After electrophoresis, proteins were transferred to polyvinylidene fluoride
221
membranes (Millipore, MA, USA). Membranes were subsequently incubated with 10% skim
222
milk dissolved in phosphate-buffered saline with Tween-20 (PBS-T) for 60 min and further
223
incubated with primary antibody in PBS-T overnight at 4°C. The membranes were washed
224
with PBS-T for 3 times and incubated with primary antibodies were as follows: [Anti-APP,
225
C-terminal (1:1000; Sigma); BACE (1:1000, Cell Signaling, Beverly, MA, USA); PS1
226
(1:1000, Cell Signaling); PS2 (1:1000, Cell Signaling); IDE (1:200, Santa Cruz, CA, USA);
227
NEP (1:1000, Millipore); RAGE (1:200, Santa Cruz); LRP-1 (1:50000, Abcam, Cambridge,
228
MA, USA); ADAM10 (1:200, Santa Cruz); and β-actin (1:200, Santa Cruz)]. After incubation
229
with appropriate secondary antibodies (1:1000, Cell Signaling) at room temperature for 1 h,
230
the membranes were visualized using pico-enhanced peroxidase detection (ELPIS-Biotech,
231
Daejeon, Korea). Western blot bands were assessed with a Davinci-Chemiluminescent
11
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
232
imaging system (CoreBio, Seoul, Korea).
233 234
Statistical analysis
235
Results were expressed as means ± SD. Statistical analysis in this present study was
236
performed using IMB SPSS statistics programs 23 (IBM Corporation, NY, USA) and SAS
237
9.4 (SAS Institute Inc., Cary, NC, USA). Statistical differences between the normal, control,
238
ALA- and DHA-administered groups were determined by one-way ANOVA followed by
239
Duncan’s post-hoc test. In the T-maze and novel object recognition test, the perceptive ability
240
between training session and test session was compared by student’s t-test. Significance was
241
set at P < 0.05.
242 243
RESULTS
244
Body weight change in Aβ25-35-inejcted mice model
245
Body weight of the mice is summarized in Table 1. During the experiment, there were no
246
significant body weight differences among the four groups.
247 248
T-maze test
249
The T-maze test, in which a mouse tends to explore an unfamiliar route, is used to assess
250
spatial discrimination. We investigated whether the oral administration of ALA reverses
251
spatial memory deficit in Aβ25-35-injected mice. In the saline-injected normal group, the
252
exploration of the previously unexplored arm was significantly higher than that of the old arm
253
(student’s t-test, p = 0.000034). In contrast, the Aβ25-35-injected mice exhibited an impaired
254
performance in the T-maze, as they showed no significant preference for the unexplored arm
12
ACS Paragon Plus Environment
Page 12 of 60
Page 13 of 60
Journal of Agricultural and Food Chemistry
255
as evidenced by the comparable the number of entries to the old arms (student’s t-test, P =
256
0.194). However, as represented in Figure 2, Aβ25-35-injected mice treated with ALA
257
significantly increased the ratio of new route entries than that of old route (student’s t-test, P
258
= 0.042), similarly to the DHA-administered group (student’s t-test, P = 0.016). This finding
259
suggested that memory dysfunction induced by Aβ25-35 was ameliorated by the administration
260
of ALA.
261 262
Novel object recognition test
263
Object perceptible ability, which is a natural tendency of mice to explore a novel object
264
instead of a familiar object, was assessed by using novel object recognition test. As shown in
265
Figure 3, normal group of mice exhibited the expected differences in the exploration ratio
266
between familiar and novel object, showing more touches to the novel object than the
267
familiar object during the test session (student’s t-test, P = 0.000298). In contrast, Aβ25-35
268
resulted in object recognition dysfunction in mice, which did not discriminate between
269
familiar and novel object (student’s t-test, P = 0.403). However, supplementation of Aβ25-35-
270
injected mice with ALA or DHA significantly increased their preference for the novel object
271
compared with familiar object as evidenced by the increased number of touches to the novel
272
object (student’s t-test, ALA: P = 0.011, DHA: P = 0.001). These results indicated that the
273
administration of ALA attenuated Aβ25-35-induced object recognition deficits.
274 275
Morris water maze test
276
To assess the long-term and spatial memory function, the Morris water maze test was carried
277
out. Mice were trained to reach the hidden platform in the water maze over 3 days. Figure 4A
13
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
278
shows that Aβ25-35-treated mice displayed a significantly longer latency to find the platform
279
compared with the normal mice. However, administration of both ALA and DHA reduced the
280
time to find the hidden platform as compared with the control group of mice. As shown in
281
Figure 4B, the saline-injected normal mice exhibited a significant decrease in time to reach
282
the hidden platform in the final test on training day 4, corresponding to 10.2 s. In contrast, the
283
Aβ25-35-treated control mice exhibited an impaired spatial memory with a latency
284
corresponding to 42 s. Compared with control group, a significant reduction in the escape
285
latency was observed in the ALA-administered group (9.6 s), as well as in the DHA-treated
286
group (9.2 s). The latency in DHA treated mice was shorter than that of the ALA-
287
administered group (F(3,16) = 14.05, P < 0.05). Furthermore, the results of the probe trial were
288
expressed as the time spent in the target quadrant where the platform was placed during the
289
training session (Fig. 4C). The Aβ25-35-injected control group exhibited a significantly
290
decreased time spent in the target quadrant, whereas mice administered with ALA or DHA
291
significantly spent more time in the area where the hidden platform had been located,
292
indicating improvement of learning and memory ability by ALA and DHA against Aβ25-35
293
injection (F(3,16) = 6.21, P < 0.05). In the visible platform, no significant differences were
294
observed among the groups to reach the platform (F(3,16) = 0.60, P > 0.1), thus they were not
295
different in visual or physical activities (Fig 4D). These results demonstrated that
296
supplementation of ALA could ameliorate Aβ25-35-induced disturbances of long-term and
297
spatial learning and memory ability.
298 299
Measurement of MDA and NO generation
300
The protective effect of ALA treatment on oxidative stress induced by Aβ25-35 was 14
ACS Paragon Plus Environment
Page 14 of 60
Page 15 of 60
Journal of Agricultural and Food Chemistry
301
investigated by measuring the levels of MDA and NO in the brain, liver and kidneys. As
302
shown in Table 2, there was a significant rise in the levels of MDA in Aβ25-35-injected brain
303
(26.16 nmol/mg protein) compared with non-injected normal brain (17.99 nmol/mg protein).
304
However ALA administration decreased the MDA concentration (20.77 nmol/mg protein),
305
almost down to the levels observed in DHA-administered mice brain, showing the MDA
306
levels of 20.42 nmol/mg protein. (F(3,20) = 5.70, P < 0.05). The MDA levels in the liver of the
307
Aβ25-35-injected group were 48.13 nmol/mg protein, which was higher than that of normal
308
group (18.71 nmol/mg protein). In contrast, MDA concentration was significantly declined by
309
administration of ALA or DHA, showing 27.68 and 20.93 nmol/mg protein, respectively
310
(F(3,20) = 190.32, P < 0.05). In addition, Aβ25-35 injection significantly increased MDA
311
concentration in the kidney, from 35.52 to 70.52 nmol/mg protein, while administration of
312
ALA or DHA decreased the MDA levels with values of 63.66 and 58.01 nmol/mg protein,
313
respectively (F(3,20) = 92.17, P < 0.05).
314
Aβ25-35 injection significantly elevated the NO levels in the brain (19.41 nmol/mg protein),
315
while levels of NO were significantly reduced in both ALA- and DHA-administered groups
316
with 16.48 and 16.90 nmol/mg protein, respectively (F(3,20) = 4.15, P < 0.05). The levels of
317
NO in the liver tissues of normal group were 17.30 nmol/mg protein compared with Aβ25-35-
318
injected control group (49.29 nmol/mg protein). Supplementation of ALA and DHA group
319
significantly attenuated NO production, with NO levels of 27.17 and 26.87 nmol/mg protein,
320
respectively (F(3,20) = 139.95, P < 0.05). Elevated NO levels in the kidneys were also observed
321
after Aβ25-35 injection (28.09 nmol/mg protein). However, ALA and DHA administration
322
significantly lowered NO levels: 24.99 and 24.79 nmol/mg protein, respectively (F(3,20) = 9.25,
323
P < 0.05). Therefore, significantly lower levels of MDA and NO in the brain, liver and
15
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
324
kidneys of the ALA-administered mice indicated that the ALA could attenuate oxidative
325
stress induced by Aβ25-35.
326
327
Effect of ALA on the amyloidogenic pathway
328
In order to investigate whether ALA influences on the amyloidogenic pathway in Aβ25-35-
329
injected mice, BACE, PS1, and PS2 protein expressions were measured by Western blotting.
330
As shown in Figure 5, significantly higher levels of BACE expression after Aβ25-35 injection
331
were apparently inhibited by ALA and DHA administration. To investigate the relationship
332
between ALA and γ-secretase activity, we measured the expression levels of PS1 and PS2, the
333
components of γ-secretase. Our results indicated significantly increased levels of both PS1
334
and PS2 in the Aβ25-35-injected mouse brain compared with normal brain. Although it did not
335
reach statistical significance in PS1 levels compared to control group, the PS2 expression was
336
noticeably decreased in the ALA-fed group of mice brain. Taken together, these data
337
suggested that ALA might contribute to the suppression of Aβ production by modulating the
338
activity of β- and γ-secretases.
339
340
Effect of ALA on the non-amyloidogenic pathway
341
To study the mechanisms related to the non-amyloidogenic pathway in Aβ25-35-injceted AD
342
mice, the protein expressions of ADAM10, sAPPα and CTFs were determined. The results
343
indicated that the expression of ADAM 10 was significantly inhibited after Aβ25-35 injection,
344
compared with the non-injected normal mice (Fig. 6). However, compared with the after
345
Aβ25-35-injected control group, the expression of ADAM10 was significantly up-regulated in 16
ACS Paragon Plus Environment
Page 16 of 60
Page 17 of 60
Journal of Agricultural and Food Chemistry
346
the ALA-administered group. Subsequently, the sAPPα and the ratio of C83/C99 protein
347
expressions in the normal group of mice were significantly elevated compared with the Aβ25-
348
35-injected
349
and C83/C99 expressions. It indicated that ALA regulated the non-amyloidogenic pathway by
350
elevating the expression levels of ADAM10, sAPPα and C83/C99 more effectively than DHA.
control group. In contrast, ALA supplementation increased the levels of sAPPα
351
352
Effect of ALA on Aβ degradation and clearance
353
Figure 7 showed the effect of ALA and DHA on protein expressions related to clearance and
354
degradation of Aβ. Following Aβ25-35 injection, the levels of NEP and IDE, which are
355
responsible for the degradation of Aβ, were decreased. However, supplementation of ALA
356
resulted in a significant up-regulation of IDE expression, but not NEP, suggesting that ALA
357
may promote Aβ degradation in the mice brain via regulation of IDE enzyme activity. We
358
also demonstrated that Aβ caused increase of the levels of RAGE (Fig. 8). However, ALA did
359
not show the effect on the level of RAGE, and LRP-1 expression was no significant
360
differences among the all groups.
361
362
DISCUSSION
363
The regulation of Aβ metabolism can be useful in inhibiting the progression of AD.
364
Recently, studies on the prevention or treatment of AD have been focused on modulating β-
365
and γ-secretases, or activating α-secretase in APP processing.55,56 Aβ25-35, a stretch of 11-
366
amino acid long residues from position 25 to 35, is produced from full-length Aβ. It has been 17
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
367
demonstrated that intracerebroventricular injection of this neurotoxic short form of Aβ could
368
induce learning and memory dysfunction.57,58 In agreement with this, our present results also
369
showed that injection of Aβ25-35-induced memory and cognitive impairments as well as
370
oxidative stress through amyloidogenesis. Therefore, we investigated the protective activity
371
and its mechanisms of ALA against Aβ25-35.
372
ALA is the mainly plant-derived essential ω-3 fatty acid. It is the precursor of DHA, and
373
considered to play a crucial role in brain development and function. However, there is still
374
limited and conflicting evidence on the function of ALA because of the low efficiency of
375
conversion of ALA to DHA, particularly in humans. Some clinical and experimental studies
376
reported that ALA-enriched diets exert beneficial effects on ischemia and stroked damage in
377
the brain.59-61 Our previous results also indicated that ALA-enriched perilla oil administration
378
effectively improved the cognitive ability in Aβ-injected mice model.38 Therefore, we
379
speculated that ALA itself may be an independent determinant of neuroprotection against Aβ-
380
induced cognitive decline. It is well established that DHA not only inhibited the Aβ
381
fibrillation but also improved neurobehavioral complications in an AD animal model.62,63
382
Therefore, we used DHA as a positive control for neuroprotection.
383
The T-maze and novel object recognition tests are based on the evidence that normal mice
384
spend longer time exploring novel route/object than familiar ones.64,65 In agreement with
385
previous studies,66,67 our results showed that Aβ25-35-injected control mice did not show
386
significant preference to the newly-introduced route/object compared with the familiar (old)
387
route/object. Interestingly, we found that both ALA- and DHA-administered mice exhibited
388
improvement of cognitive performances and memory ability in both the T-maze and novel
389
object recognition tests as evidenced by the high exploring rate of the unfamiliar route/object. 18
ACS Paragon Plus Environment
Page 18 of 60
Page 19 of 60
Journal of Agricultural and Food Chemistry
390
Furthermore, we performed Morris water maze test to determine whether ALA improved
391
spatial learning and long-term memory function in the Aβ25-35-injected mice. The result of
392
present study revealed that memory dysfunction was observed in the mice injected with Aβ25-
393
35,
394
quadrant compared with normal group. However, ALA administration reversed these effects
395
and resulted in significantly shorter escape latencies and prolonged time in the target quadrant
396
than in Aβ25-35-injected control mice. These behavioral neuroprotective effects of ALA in line
397
with recent findings that perilla or ALA diet reversed the impairments in the Morris water
398
maze or T-maze tests after stroke.68,69 Our present findings also provided further evidence on
399
the neuroprotective role of ALA against the Aβ25-35 associated learning and memory
400
dysfunction.
as shown by the increased escape latency and decreased time to spent in the target
401
Brain consists largely of lipids and is easily damaged by free radicals compared to other
402
tissues under physiological conditions. Aβ is neurotoxic and induces oxidative stress in the
403
brain. During this process, MDA, which is the final product of membrane lipid peroxidation,
404
is an important index for determining the level of oxidative stress. In addition, NO has been
405
recognized as a toxic reactive free-radical in the central nervous system. According to this
406
evidence, it has been suggested that the production of NO could influence the cognitive
407
deficits.70 In the current study, we investigated the protective effect of ALA against lipid
408
peroxidation and NO production in the brain, liver and kidneys of Aβ25-35–injected mice. Our
409
results indicated that Aβ25-35 produced high concentrations of NO in the brain, liver and
410
kidneys, whereas ALA or DHA supplemented group prevented excessive NO production.
411
These results can be possible due to our previous result that administration of perilla oil
412
markedly inhibited Aβ25-35-induced NO production via suppression of iNOS and COX-2 19
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
413
protein expression.38 In addition, several studies have also shown the protective role of ALA
414
on NO generation by blocking iNOS, COX-2 or NF-κB activation in inflammation models.71-
415
72
416
kidneys. In contrast, ALA or DHA administration suppressed the generation of MDA, which
417
suggest that ALA or DHA administration exerts protective effects against lipid peroxidation
418
against Aβ25-35. It has been reported that dietary DHA exerts a protective role from AD by
419
acting as a precursor for neuroprotection against oxidative stress; its mechanism may be
420
attributed to the promotion of antioxidant enzymes.73-75 Moreover, ω-3 fatty acids decreased
421
production of superoxide anion, lactate dehydrogenase, and thiobarbituric acid reactive
422
substances (TBARS) as compared with ω-6 fatty acids.76 From this point of view, the
423
correlation between NO/TBARS and ALA in the present results suggested that the
424
antioxidant effect of ALA may contribute to reduction of cognitive dysfunction in Aβ25-35-
425
infused AD mouse. Indeed, ALA efficacy was confirmed to be at the level of DHA, which
426
was used as a positive control for neuroprotection.
After Aβ25-35 injection, the level of MDA significantly increased in the mice brain, liver and
427
Since our results demonstrated a beneficial role of ALA in the cognitive improvement
428
against Aβ25-35, we assessed the underlying mechanisms of ALA protective actions. The
429
injection of Aβ could induce the amyloidogenic pathway involving the cleavage of BACE
430
and further γ-secretase processing.77 However, administration of ALA resulted in the down-
431
regulation of Aβ25-35-induced BACE and PS2 overexpressions. Similar changes were also
432
observed after DHA administration. Grimm et al.78 also demonstrated that DHA suppressed
433
β- or γ-secretase activity both in SH-SY5Y cells and mice brains. These results suggested that
434
both ALA and DHA inhibited the amyloidogenic pathway by decreasing the activity of β- and
435
γ-secretases. The modulation of α-secretase can be a potential candidate for treating AD.79 20
ACS Paragon Plus Environment
Page 20 of 60
Page 21 of 60
Journal of Agricultural and Food Chemistry
436
Although Aβ is toxic, both sAPPα and C83 exert neuro-protective effects through the
437
stimulation of neurite outgrowth and neuronal survival.80 We measured the levels of sAPPα,
438
CTFs, and ADAM10 expressions, which represent alterations in APP processing to the non-
439
amyloidogenic pathway. As compared with control mice, ALA and DHA administration
440
enhanced the expression levels of sAPPα. Furthermore, ALA also significantly increased the
441
levels of C83/C99 and ADAM10, while DHA did not so to a lesser extent. Our findings
442
revealed that ALA could suppress the activity of β- and γ-secretases and it could also be
443
involved in the enhancement of α-secretase activity.
444
Recent studies have highlighted not only the link between Aβ and AD pathology but also
445
the involvement of Aβ production, clearance, and efflux. The reduction of Aβ accumulation
446
occurs through Aβ clearance mechanisms, such as up-regulating Aβ cleaving enzymes, IDE
447
and NEP.81,82 We examined the effect of ALA on the degradation and clearance of Aβ. Lim et
448
al.83 demonstrated that DHA-fed Tg2576 mice exhibited up-regulation of IDE. In our results,
449
Aβ-injected mice showed a decreased IDE and NEP protein expressions compared with
450
normal mice. This tendency was consistent with previous findings, in which the levels of IDE
451
and NEP continually decreased during the progression of AD.84,85 However, ALA- and DHA-
452
administered groups exhibited a reduced inhibition of IDE, thereby lowering Aβ deposition in
453
the mouse brain. On the other hand, the differences in NEP expression were not significant
454
both after ALA- and DHA-administration, compared with the control mice. These results
455
suggested that ALA may inhibit Aβ accumulation, mediated by down-regulation of IDE
456
expression in the brain.
457
RAGE and LRP-1 perform opposite functions into Aβ transportation in the brain. RAGE,
458
which plays a key role in Aβ influx, promotes Aβ transcytosis into the BBB and contributes 21
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
459
to its transport into the central nervous system.86 On the other hand, LRP-1 clears Aβ from
460
the brain to the blood across the BBB.87 Our results showed that the expression of RAGE was
461
up-regulated in Aβ25-35-injected mice, compared with the normal group. RAGE expression
462
was reduced in mice administered with DHA, but not in those treated with ALA. We did not
463
find any significant changes in level of LRP-1 among all groups.
464
Aβ25-35 is a fragment of full-length Aβ1-42. It has been shown that injection of this peptide
465
into the cerebral ventricle induces neurotoxic effects similar to Aβ1-42 or Aβ1-40. Previous
466
evidences provided that injection of Aβ25-35 is able to elicit the up-regulation of APP and
467
endogenous production of Aβ.88,89 According to Tsuruma et al.,90 Aβ25-35 increased
468
intracellular Aβ1-42 or Aβ1-40, and β- and γ-secretase were activated or up-regulated caused by
469
Aβ stimulation. In addition, injection of Aβ25-35 results in behavioral alterations and modified
470
APP processing through activation of amyloidogenic pathway (up-regulation of C99 levels).91
471
Further study has to be conducted to determine whether ALA shows same biophysiological
472
changes on APP processing and Aβ metabolism using Aβ1-40 or Aβ1-42 peptide.
473
Our study demonstrated that administration of ALA prevented learning and memory
474
impairments in the AD mouse model as evidenced by their performance on the T-maze, novel
475
object recognition, and Morris water maze test. ALA attenuated Aβ25-35–induced oxidative
476
stress by inhibiting the overproduction of MDA and NO levels in the brain, liver and kidneys.
477
These findings provided evidence that ALA may be a potentially valuable source for the
478
treatment of AD. Furthermore, these protective effects of ALA are related to the regulation of
479
APP processing by non-amyloidogenic pathway (down-regulation of BACE, PS2; up-
480
regulation of sAPPα, C83/C99 and ADAM10 protein expressions), as well as increase
481
expression of degrading Aβ enzyme, IDE. In conclusion, the present study indicated that 22
ACS Paragon Plus Environment
Page 22 of 60
Page 23 of 60
Journal of Agricultural and Food Chemistry
482
ALA could protect from cognitive dysfunction and memory impairment against Aβ25-35, and
483
these beneficial effects are comparable to those of DHA.
484
485
ABBREVIATIONS USED
486
Aβ, amyloid beta; AD, Alzheimer’s disease; ADAM, A distintegrin and metalloprotease; ALA,
487
alpha-linolenic acid; APP, amyloid precursor protein; BACE, β-site APP cleaving enzyme;
488
BBB, blood-brain-barrier; C83, C-terminal fragment alpha; C99, C-terminal fragment beta;
489
DHA, docosahexahenoic acid; IDE, insulin-degrading enzyme; LRP-1, low-density
490
lipoprotein receptor-related protein-1; MDA, malondialdehyde; NaCl, Sodium chloride;
491
NaNO2, sodium nitrite; NEP, neprilysin; NO, nitric oxide; PBS-T, phosphate-buffered saline
492
with Tween-20; PS, presenilin; RAGE, receptor for advanced end glycation; sAPPα, soluble
493
neurotrophic fragment; SDS-PAGE, sulfate polyacrylamide gel electrophoresis; TBA,
494
thiobarbituric acid; TBARS, thiobarbituric reactive substances
495
496
ACKNOWLEDGMENTS
497
This work was carried out with the support of the “Cooperative Research Program for
498
Agriculture Science & Technology Development (PJ01015603),” Rural Development
499
Administration, Republic of Korea.
23
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
500
REFERENCES
501
(1) Glenner, G. G.; Wong, C. W.; Quaranta, V.; Eanes, D. E. The amyloid deposits in
502
Alzheimer’s disease: Their nature and pathogenesis. Appl. Pathol. 1984, 2, 357-369.
503
(2) Hensley, K.; Hall, N.; Subramaniam, R.; Cole, P.; Harris, M.; Aksenob, M.; Aksenova,
504
M.; Gabbita, P.; Wu, J. F.; Carney, J. M.; Lovell, M.; Markesbery, W. R.; Butterfield, D.
505
A. Brain regional correspondence between Alzheimer’s disease histopathology and
506
biomarkers of protein oxidation. J. Neurochem. 1995, 65, 2146-2156.
507 508
(3) Butterfield, D. A. β-amyloid-associated free radical oxidative stress and neurotoxicity: Implication for Alzheimer’s disease. Chem. Res. Toxicol. 1997, 10, 495-506.
509
(4) Butterfield, D. A.; Castegna, A.; Lauderback, C. M.; Drake, J. Evidence that amyloid
510
beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain
511
contribute to neuronal death. Neurobiol. Aging 2002, 23, 655-664.
512 513
514 515
516 517
(5) Cai, Z.; Zhao, B.; Ratka, A. Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromolecular Med. 2011, 313, 223-250. (6) Millucci, L.; Ghezzi, L.; Bernardini, G.; Santucci, A. Conformations and biological activities of amyloid beta peptide 25-35. Curr. Protein Pept. Sci. 2009, 11, 54-67. (7) Zhang, Y.; Thompson, R.; Zhang, H.; Xu, H. APP processing in Alzheimer’s disease. Mol. Brain 2011, 4, 3.
518
(8) He, G.; Luo, W.; Li, P.; Femmers, C.; Netzer, W.; Hendrick, J.; Bettayeb, K.; Flajolet, M.;
519
Gorelick, F.; Wennogle, L. P.; Greengard, P. Gamma-secretase activating protein, a 24
ACS Paragon Plus Environment
Page 24 of 60
Page 25 of 60
520
Journal of Agricultural and Food Chemistry
therapeutic target for Alzheimer’s disease. Nature 2010, 467, 95-98.
521
(9) Postina, R.; Schroeder, A.; Dewachter, I.; Bohl, J.; Schmitt, U.; Kojro, E.; Prinzen, C.;
522
Endres, K.; Hiemke, C.; Blessing, M.; Flamez, P.; Dequenne, A.; Godaux, E.; van Leuven,
523
F.; Fahrenholz, F. A disintegrin-metalloproteinase prevents amyloid plaque formation and
524
hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 2004, 113,
525
1456–1464.
526 527
(10)Wang, Y. J.; Zhou, H. D.; Zhou, X. F.; Clearance of amyloid-beta in Alzheimer’s disease: progress, problems and perspectives. Drug Discov. Today 2006, 11, 931-938.
528
(11)Donahue, J. E.; Flaherty; S. L.; Johanson, C. E.; Duncan Ⅲ, J. A.; Silvergerg, G. E.;
529
Miller M. C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E. G.
530
RAGE, LRP-1 and amyloid-beta protein in Alzheimer’s disease. Acta. Neuropathol. 2006,
531
112, 405-415.
532 533
534 535
536
(12)Schulz, V. Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. Phytomedicine 2003, 10, 74-79. (13)Birks, J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006, 1, CD005593. (14)Obregon, D. F.; Rezai-Zadeh, K.; Bai, Y.; Sun, N.; Hou, H.; Ehrhart, J.; Zeng, J.; Mori, T.;
537
Arendash, G. W.; Shytle, D.; Town, T.; Tan, J. ADAM 10 activation is required for green
538
tea (-)-epigallocatechin-3-gallate-induced α-secretase cleavage of amyloid precursor
539
protein. J. Biol. Chem. 2006, 281, 16419-16427.
540
(15)Rezai-Zadeh, K.; Arendash, G. W.; Hou, H.; Femandez, F.; Jensen, M.; Runfeldt, M.; 25
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
541
Shytle, R.; Tan, J. Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid
542
mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic
543
mice. Brain Res. 2008, 1214, 177-187.
544
(16)Rezai-Zadeh, K.; Douglas Shytle, R.; Bai, Y.; Tian, J.; Hou, H.; Mori, T.; Zeng, J.;
545
Obregon, D.; Town, T.; Tan, J. Flavonoid-mediated presenilin-1 phosphorylation reduces
546
Alzheimer’s disease β-amyloid production. J. Cell. Mol. Med. 2009, 13, 574-588.
547
(17)Shi, C.; Zheng, D.; Fang, L.; Wu, F.; Kwong, W. H.; Xu, J. Ginsenoside Rg1 promotes
548
nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and
549
PI3K/Akt. BBA-Gen. Subjects 2012, 1820, 453-460.
550
(18)Grimm, M. O.; Grimm, H. S.; Tomic, I.; Beyreuther, K.; Harrtmann, T.; Bergmann, C.
551
Independent inhibition of Alzheimer disease β- and γ-secretase cleavage by lowered
552
cholesterol levels. J. Biol. Chem. 2008, 283, 11302-11311.
553
(19)Grimm, M. O.; Haupenthal, V. J.; Rothhaar, T. L.; Zimmer, V. C.; Grösgen, S.;
554
Hundsdörfer, B.; Lehmann, J.; Grimm, H. S.; Hartmann, T. Effect of different
555
phospholipids on α-secretase activity in the non-amyloidogenic pathway of Alzheimer’s
556
disease. Int. J. Mol. Sci. 2013, 14, 5879-5898.
557
(20)Http://clinicaltrials.gov
558
(21)Waite, L. M. Treatment for Alzheimer’s disease: has anything changed? Aust. Prescr.
559
2015, 38, 60-63.
560
(22)Postina, R. Activation of α-secretase cleavage. J. Neurochem. 2012, 120, 46-54.
561
(23)Mennitti, L. V.; Oliveira, J. L.; Morais, C. A.; Estadella, D.; Oyama, L. M.; Oller do 26
ACS Paragon Plus Environment
Page 26 of 60
Page 27 of 60
Journal of Agricultural and Food Chemistry
562
Nascimento, C. M.; Pisani, L. P. Type of fatty acids in maternal diets during pregnancy
563
and/or lactation and metabolic consequences of the offspring. J. Nutr. Biochem. 2015, 26,
564
99-111.
565 566
567 568
569 570
571 572
573 574
575 576
(24)Calder, P. C. Functional roles of fatty acids and their effects on human health. JPEN J. Parenter. Enteral Nutr. 2015, 39, 18S-32S. (25)Kelley, D. S. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 2001, 17, 669-673. (26)Simopoulos, A. P. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 1999, 70, 560S-569S. (27)Cederholm, T.; Salem, N.; Palmblad, J. ω-3 fatty acids in the prevention of cognitive decline in humans. Adv. Nutr. 2013, 4, 672-676. (28)Swanson, D.; Block, R.; Mousa, S. A. Omega-3 fatty acids EPA and DHA: Health benefits throughout life. Adv. Nutr. 2012, 3, 1-7. (29)Connor, W. E. Importance of n-3 fatty acids in health and disease. Am. J. Clin. Nutr. 2000, 71, 1715-1755.
577
(30)Yashodhara, B. M.; Umakanth, S.; Pappachan, J. M.; Bhat, S. K.; Kamath, R.; Choo, B.
578
H. Omega-3 fatty acids: a comprehensive review of their role in health and disease.
579
Postgrad. Med. J. 2009, 85, 84-90.
580 581
(31)Calder, P. C. Very long chain omega-3 (n-3) fatty acids and human health. Eur. J. Lipid Sci. Technol. 2014, 116, 1280-1300.
27
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
582 583
584 585
586 587
(32)Adkins, Y.; Kelley, D. S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J. Nutr. Biochem. 2010, 21, 781-792. (33)SanGiovanni, J. P.; Chew, E. Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Retin Eye Res. 2005, 24, 87-138. (34)Mozaffarian, D.; Rimm, E. B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296, 1885-1899.
588
(35)Zhao, G.; Etherton, T. D.; Martin, K. R.; West, S. G.; Gillies, P. J.; Kris-Etherton, P. M.
589
Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in
590
hypercholesterolemic men and women. J. Nutr. 2004, 134, 2991-2997.
591
(36)Nguemeni, C.; Delplanque, B.; Rovère, C.; Simon-Rousseau, N.; Gandin, C.; Agnani, G.;
592
Nahon, J. L.; Heurteaux, C.; Blondeau, N. Dietary supplementation of alpha-linolenic
593
acid in an enriched rapeseed oil diet protects from stroke. Pharmacol. Res. 2010, 61, 226-
594
233.
595
(37)Gao, H.; Yan, P.; Zhang, S.; Haung, H.; Huang, F.; Sun, T.; Deng, Q.; Huang, Q.; Chen,
596
S.; Ye, K.; Xu, J.; Liu, L. Long-term dietary alpha-linolenic acid supplement alleviates
597
cognitive impairment correlate with activating hippocampal CREB signaling in natural
598
aging rats. Mol. Neurobiol. 2016, 53, 4772-4786.
599
(38)Lee, A. Y.; Choi, J. M.; Lee, J.; Lee, M. H.; Lee, S.; Cho, E. J. Effects of vegetable oils
600
with different fatty acid compositions on cognition and memory ability in Aβ25-35-inudced
601
Alzheimer’s disease mouse model. J. Med. Food 2016, 19, 912-921.
602
(39)Singh, M. Essential fatty acids, DHA and human brain. Indian J. Pediatr. 2005, 72, 23928
ACS Paragon Plus Environment
Page 28 of 60
Page 29 of 60
603
Journal of Agricultural and Food Chemistry
242.
604
(40)Sun, G. Y.; Simonyi, A.; Frtsche, K. L.; Chuang, D. Y.; Hannink, M.; Gu, Z.; Greenlief,
605
M.; Yao, J. K.; Lee, J. C.; Beversdorf, D. Q. Docosahexaenoic acid (DHA): An essential
606
nutrient and a nutraceutical for brain health and diseases. Prostaglandins Leukot. Essen.
607
Fatty Acids 2017, In press.
608 609
610 611
(41)Lukiw, W. J.; Bazan, N. G. Docosahexaenoic acid and the aging brain. J. Nutr. 2008, 138, 2510-2514. (42)Swanson, D.; Block, R.; Mousa, S. A. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv. Nutr. 2012, 3, 1-7.
612
(43)Barcelό-Coblijin, G.; Murphy, E. J. Alpha-linolenic acid and its conversion to longer
613
chain n-3 fatty acids: Benefits for human health and a role in maintaining tissue n-3 fatty
614
acids levels. Prog. Lipid Res. 2009, 48, 355-374.
615 616
(44)Burdge, G. C.; Calder, P. C. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev. 2005, 45, 581-597.
617
(45)Francois, C. A.; Connor, S. L.; Bolewicz, L. C.; Connor, W. E. Supplementing lactating
618
women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am. J.
619
Clin. Nutr. 2003, 77, 226-233.
620 621
622 623
(46)Arterburn, L. M.; Hall, E. B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 2006, 83, 1467S-1476S. (47)Lee, J.; Lee, M. H.; Cho, E. J.; Lee, S. High-yield methods for purification of α-linolenic acid from Perilla frutescens var. japonica oil. Appl. Biol. Chem. 2016, 59, 89-94. 29
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
624
(48)Maurice, T.; Lockhart, B. P.; Privat, A. Amnesia induced in mice by centrally
625
administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996, 706,
626
181-193.
627 628
629 630
631 632
633 634
635 636
(49)Laursen, S. E.; Belknap, J. K. Intracerebroventricular injections in mice. Some methodological refinements. J. Pharmacol. Method 1986, 16, 355-357. (50)Montgomery, K. C. A test of two explanations of spontaneous alternation. J. Comp. Physiol. Psych. 1952, 45, 287-293. (51)Bevins, R. A.; Besheer, J. Object recognition in rats and mice: a one-trial non-matchingto-sample learning task to study 'recognition memory'. Nat. Protoc. 2006, 1, 1306-1311. (52)Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Meth. 1984, 11, 47-60. (53)Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358.
637
(54)Schmidt, H. H.; Warner, T. D.; Nakane. M.; Förstermann, U.; Murad, F. Regulation and
638
subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Mol.
639
Pharmacol. 1992, 41, 615-624.
640 641
642 643
(55)Bertram, L.; Tanzi, R. E. Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 2008, 9, 768-778. (56)Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010, 9, 702-716.
30
ACS Paragon Plus Environment
Page 30 of 60
Page 31 of 60
Journal of Agricultural and Food Chemistry
644
(57)Kubo, T.; Nishimura, S.; Kumagae, Y.; Kaneko, I. In vivo conversion of racemized β-
645
amyloid ([D-Ser26]Aβ1-40) to truncated and toxic fragments ([D-Ser26]A25-35/40) and
646
fragment presence in the brains of Alzheimer’s patients. J. Neurosci. Res. 2002, 70, 474-
647
483.
648
(58)Yamada, M.; Chiba, T.; Sasabe, J.; Nawa, M.; Tajima, H.; Niikura, T.; Terashita, K.; Aiso,
649
S.; Kita, Y.; Matsuoka, M.; Nishimoto, I. Implanted cannula-mediated repetitive
650
administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial
651
working memory. Behav. Brain Res. 2005, 164, 139-146.
652
(59)Heurteaux, C.; Laigle, C.; Blondeau, N.; Jarretou, G.; Lazdunski, M. Alpha-linolenic acid
653
and riluzole treatment confer cerebral protection and improve survival after focal brain
654
ischemia. Neuroscience 2006, 137, 241-251.
655
(60)Nguemeni, C.; Gouix, E.; Bourourou, M.; Heurteaux, C.; Blondeau, N. Alpha-linolenic
656
acid: a promising nutraceutical for the prevention of stroke. Phrmacol. Res. 2010, 61,
657
226-233.
658 659
(61)Blondeau, N. The nutraceutical potential of omega-3 alpha-linolenic acid in reducing the consequences of stroke. Biochimie 2016, 120, 49-55.
660
(62)Hashimoto, M.; Hossain, S.; Agdul, H.; Shido, O. Docosahexaenoic acid-induced
661
amelioration on impairment of memory learning in amyloid β-infused rats relates to the
662
decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions.
663
BBA-Mol. Cell. Biol. L. 2005, 1738, 91-98.
664
(63)Hashimoto, M.; Shahdat, H. M.; Katakura, M.; Tanabe, Y.; Gamoh, S.; Miwa, K.; 31
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
665
Shimada, T.; Shido, O. Effects of docosahexaenoic acid on in vitro amyloid beta peptide
666
25-35 fibrillation. BBA-Mol. Cell. Biol. L. 2009, 1791, 289-296.
667 668
(64)Ennaceur, A.; Delacour, J. A new one-trial test for neurobiological studies ofmemory in rats. 1: behavioral data. Behav. Brain Res. 1988, 31, 47–59.
669
(65)Davis, S.; Renaudineau, S.; Poirier, R.; Poucet, B.; Save, E.; Laroche, S. The formation
670
and stability of recognition memory: what happens upon recall? Front. Behav. Neurosci.
671
2010, 4, 177.
672
(66)Choi, Y. Y.; Maeda, T.; Fujii, H.; Yokozawa, T.; Kim, H. Y.; Cho, E. J.; Shibamoto, T.
673
Oligonol improves memory and cognition under an amyloid β25-35-induced Alzheimer’s
674
mouse model. Nutr. Res. 2014, 34, 595-603.
675
(67)Choi, J. Y.; Cho, E. J.; Lee, H. S.; Lee, J. M.; Yoon, Y. H.; Lee, S. Tartary buckwheat
676
improves cognition and memory function in an in vivo amyloid-β-induced Alzheimer
677
model. Food Chem. Toxicol. 2013, 53, 105-111.
678
(68) Bourourou, M.; Heurteaux, C.; Blondeau, N. Alpha-linolenic acid given as enteral or
679
parenteral nutritional intervention against sensorimotor and cognitive deficits in a mouse
680
model of ischemic stroke. Neuropharmacology 2016, 108, 60-72.
681
(69)Lee, J.; Park, S.; Lee, J. Y.; Yeo, Y. K.; Kim, J. S.; Lim, J. Improved spatial learning and
682
memory by perilla diet is correlated with immunoreactivities to neurofilament and α-
683
synuclein in hilus of dentate gyrus. Proteome Sci. 2012, 10, 1-12.
684
(70)Diaz, A.; Mendieta, L.; Zenteno, E.; Guevara, J.; Limon, I. D. The role of NOS in the
685
impairment of spatial memory and damaged neurons in rats injected with amyloid 32
ACS Paragon Plus Environment
Page 32 of 60
Page 33 of 60
686
Journal of Agricultural and Food Chemistry
beta25-35 into the temporal cortex. Pharmacol. Biochem. Behav. 2011, 98, 67-75.
687
(71)Reifen, R.; Karlinsky, A.; Stark, A. H.; Berkovich, Z.; Nyska, A. α-linolenic acid (ALA)
688
is an anti-inflammatory agent in inflammatory bowel disease. J. Nutr. Biochem. 2005, 26,
689
1632-1640.
690
(72)Ren, J.; Chung, S. H. Anti-inflammatory effect of α-linolenic acid and its mode of action
691
through the inhibition of nitric oxide production and inducible nitric oxide synthase gene
692
expression via NF-κB and mitogen-activated protein kinase pathways. J. Agric. Food
693
Chem. 2007, 55, 5073-5080.
694
(73)Hossain, M. S.; Hashimoto, M.; Gamoh, S.; Masumura, S. Antioxidative effects of
695
docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged
696
hypercholesterolemic rats. J. Neurochem. 1999, 72, 1133-1138.
697 698
(74)Bazan, N. G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Nerusci. 2006, 29, 263-271.
699
(75)Lukiw, W. J.; Cui, J. G.; Marcheselli, V. L.; Bodker, M.; Botkjaer, A.; Gotlinger, K.;
700
Serhan, C. N.; Bazan, N. G. A role for docosahexaenoic acid-derived neuroprotectin D1
701
in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115, 2774.
702 703
(76)Richard, D.; Kefi, K.; Barbe, U.; Visioli, F. Polyunsaturated fatty acids as antioxidants. Pharmacol. Res. 2008, 57, 451-455.
704
(77)Yun, H. M.; Kim, H. S. Park, K. R.; Shin, J. M.; Kang, A. R.; Lee, K. I.; Song, S.; Kim, Y.
705
B.; Han, S. B.; Chung, H. M.; Hong, J. T. Placenta-derived mesechymal stem cells
706
improve memory dysfunction in an Aβ1-42-infused mouse model of Alzheimer’s disease. 33
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
707
Cell Death Dis. 2013, 4, e958.
708
(78)Grimm, M. O.; Kuchenbecker, J.; Grösgen, S.; Burg, V. K.; Hundsdörfer, B.; Rothhaar, T.
709
L.; Friess, P.; de Wilde, M. C.; Broersen, L. M.; Penke, B.; Péter, M.; Vigh, L.; Grimm, H.
710
S.; Hartmann, T. Docosahexaenoic acid reduces amyloid β production via multiple
711
pleiotropic mechanisms. J. Biol. Chem. 2011, 286, 14028-14039.
712 713
(79)Nunan, J.; Small, D. H. Regulation of APP cleavage by α-, β-, and γ-secretases. FEBS Lett. 2000, 483, 6-10.
714
(80) Tyan, S. H.; Shih, A. Y. J.; Walsh, J. J.; Maruyama, H.; Sarsoza, F.; Ku, L.; Eggert, S.;
715
Hof, P. R.; Koo, E. H.; Dickstein, D. L. Amyloid precursor protein (APP) regulates
716
synaptic structure and function. Mol. Cell. Neurosci. 2012, 51, 43-52.
717
(81)Vekrellis, K.; Ye, Z.; Qiu, W. Q.; Walsh, D.; Hartley, D.; Chesneau, V.; Rosner, M. R.;
718
Selkoe, D. J. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by
719
insulin-degrading enzyme. J. Neurosci. 2000, 20, 1657-1665.
720
(82)Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N. P.; Gerard, C.; Hama,
721
E.; Lee, H. J.; Saido, T. C. Metabolic regulation of brain Aβ by neprilysin. Science 2001,
722
292, 1550-1552.
723
(83)Lim, G. P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; Salem, N.; Frautschy,
724
S. A.; Cole, G. M. A diet enriched with the Omega-3 fatty acid docosahexaenoic acid
725
reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25, 3032-
726
3040.
727
(84)Marr, R. A.; Guan, H.; Rockenstein, E.; Kindy, M.; Gage, F. H.; Verma, I.; Masliah, E.; 34
ACS Paragon Plus Environment
Page 34 of 60
Page 35 of 60
Journal of Agricultural and Food Chemistry
728
Hersh, L. B. Neprilysin regulates amyloid beta peptide levels. J. Mol. Neurosci. 2004, 22,
729
5-11.
730
(85)Bulloj, A.; Leal, M. C.; Xu, H.; Castaño, E. M.; Morelli, L. Insulin-degrading enzyme
731
sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading
732
protease. J. Alzheimer’s Dis. 2010, 19, 79-95.
733
(86)Deane, R.; Du Yan, S.; Submamaryan, R. K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch,
734
D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Marie
735
Schmidt, A.; Armstrong, D. L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.;
736
Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-β peptide transport across
737
the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9, 907-913.
738
(87)Shibata, M.; Yamada, S.; Ram Kumar, S.; Calero, M.; Badding, J.; Frangione, B.;
739
Holtzman, D. M.; Miller, C. A.; Strickland, D. K.; Ghiso, J.; Zlokovic, B. V. Clearance of
740
Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the
741
blood-brain barrier. J. Clin. Invest. 2000, 106, 489-499.
742
(88)Whitehead, S. N.; Hachinski, V. C.; Cechetto, D. F. Interaction between a rat model of
743
cerebral ischemia and beta-amyloid toxicity: inflammatory responses. Stroke 2005, 36,
744
107-112.
745
(89)Cheng, G.; Whitehead, S. N.; Hachinski, V.; Cechetto, D. F. Effects of pyrrolidine
746
dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory
747
deficits in the rat. Neurobiol. Dis. 2006, 23, 140-151.
748
(90)Tsuruma, k.; Tanaka, Y.; Shimazawa, M.; Hara, H. Inudction of amyloid precursor 35
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
749
protein by the neurotoxic peptide, amyloid beta-25-35, causes retinal ganglion cell death.
750
J. Neurochem. 2010, 113, 1545-1554.
751
(91)Zussy, C.; Brureau, A.; Delair, B.; Marchal, S.; keller, E.; Lxart, G.; Naert, G.; Meunier,
752
J.; Chevallier, N.; Maurice, T.; Givalois, L. Time-course and regional analyses of the
753
physiopathological changes induced after cerebral injection of an amyloid β fragment in
754
rats. Am. J. Pathol. 2011, 179, 315-334.
755
36
ACS Paragon Plus Environment
Page 36 of 60
Page 37 of 60
Journal of Agricultural and Food Chemistry
756
FIGURE CAPTIONS
757
Figure 1. Behavioral experimental schedule for mice injected with Aβ25-35.
758
759
Figure 2. Effects of alpha-linolenic acid on the spatial perceptive ability in the T-maze test in
760
Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The space perceptive abilities
761
for old and new routes are significantly different as determined by Student’s t-test (P < 0.05).
762
ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration
763
of docosahexaenoic acid (100 mg/kg/day).
764
765
Figure 3. Effects of alpha-linolenic acid on recognition memory in the novel object
766
recognition test in Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The object
767
perceptive abilities for familiar and novel objects are significantly different as determined by
768
student’s t-test (P < 0.05). ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day)
769
DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day).
770
771
Figure 4. (A) Effects of alpha-linolenic acid on escape latency to the platform in the Morris
772
water maze test in Aβ25-35-injected mice. (B) Effects of alpha-linolenic acid on latency to
773
reach the hidden platform in the Morris water maze test on the final test day in Aβ25-35-
774
injected mice. (C) Effects of alpha-linolenic acid on occupancy time of the target quadrant in
775
the Morris water maze test in Aβ25-35-injected mice. The percentage of time spent in the target
776
quadrant was calculated in the water maze test on the final test day. (D) Effects of alpha37
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 38 of 60
777
linolenic acid on latency to reach the exposed platform in the Morris water maze test in Aβ25-
778
35-injected
779
significantly different (P < 0.05) from each other. NS: No significance ALA: Oral
780
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
781
docosahexaenoic acid (100 mg/kg/day).
mice. Data represent mean ± SD (n=5).
a-b
Means with different letters are
782
783
Figure 5. Effects of alpha-linolenic acid on BACE, PS1 and PS2 protein expression levels in
784
the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
785
letters are significantly different (P < 0.05) from each group. ALA: Oral administration of
786
alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid
787
(100 mg/kg/day).ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA:
788
Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading
789
control.
a-d
Means with different
790
791
Figure 6. Effects of alpha-linolenic acid on sAPPα, CTFs, and ADAM10 protein expression
792
levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
793
different letters are significantly different (P < 0.05) from each group. ALA: Oral
794
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
795
docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control.
796
38
ACS Paragon Plus Environment
a-d
Means with
Page 39 of 60
Journal of Agricultural and Food Chemistry
797
Figure 7. Effects of alpha-linolenic acid on IDE and NEP protein expression levels in the
798
Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
799
are significantly different (P < 0.05) from each group. ALA: Oral administration of alpha-
800
linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100
801
mg/kg/day). β-actin was used as a loading control.
a-c
Means with different letters
802
803
Figure 8. Effects of alpha-linolenic acid on RAGE and LRP-1 protein expression levels in
804
the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
805
letters are significantly different (P < 0.05) from each group. NS: No significance. ALA: Oral
806
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
807
docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control.
39
ACS Paragon Plus Environment
a-c
Means with different
Journal of Agricultural and Food Chemistry
808
Page 40 of 60
Table 1. Change of body weight in Aβ25-35-injected mice Body weight (g) Group Stocked day
NS
Injection
33.82 ± 2.81
NS
Oral
Behavioral
administration
experiment
33.97 ± 2.38
NS
35.50 ± 2.71
Dissection
NS
35.50 ± 2.90
NS
Normal
25.13 ± 1.72
Control
24.83 ± 1.34
33.75 ± 1.34
33.93 ± 1.65
35.80 ± 1.63
36.47 ± 1.07
ALA
25.60 ± 1.07
32.48 ± 0.72
34.15 ± 1.66
35.80 ± 1.89
33.90 ± 2.08
DHA
25.43 ± 1.35
32.87 ± 2.04
34.22 ± 2.45
34.58 ± 2.68
34.47 ± 3.07
809
Data are presented as mean ± SD (n=6). NS: No significance. ALA: Oral administration of
810
alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid
811
(100 mg/kg/day).
40
ACS Paragon Plus Environment
Page 41 of 60
Journal of Agricultural and Food Chemistry
812
Table 2. Effect of alpha-linolenic acid on lipid peroxidation (A) and NO generation (B)
813
in the brain, liver and kidney of Aβ25-35-injected mice. (A) MDA (nmol/mg protein) Group Brain
Liver b
Normal
17.99 ± 5.68
Control
26.16 ± 0.97a
ALA
20.77 ± 3.85
DHA
20.42 ± 1.39b
Kidney c
b
d
18.71 ± 2.05
35.52 ± 3.82
48.13 ± 2.43a
70.52 ± 2.83a
b
b
27.68 ± 1.89
63.66 ± 3.97
20.93 ± 2.99c
58.01 ± 4.63c
(B) NaNO2 (nmol/mg protein) Group Brain
Liver
Kidney
Normal
16.74 ± 1.04b
17.30 ± 0.96c
20.59 ± 0.80c
Control
19.41 ± 1.14
ALA
DHA
a
a
a
49.29 ± 4.83
28.09 ± 0.62
16.48 ± 2.70b
27.17 ± 1.67b
24.99 ± 4.76b
16.90 ± 0.93b
26.87 ± 2.12b
24.79 ± 0.98b
814 a-d
815
Data are presented as mean ± SD (n=6).
816
different (P < 0.05) from each group. ALA: Oral administration of alpha-linolenic acid (100
817
mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day).
Means with different letters are significantly
41
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
818 819
Figure 1. Behavioral experimental schedule for mice injected with Aβ25-35.
42
ACS Paragon Plus Environment
Page 42 of 60
Page 43 of 60
Journal of Agricultural and Food Chemistry
60
*
*
*
Space perceptive ability (%)
50
40 old route 30
new route
20
10
0 Normal
Control
ALA
DHA
820 821
Figure 2. Effects of alpha-linolenic acid on the spatial perceptive ability in the T-maze test in
822
Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The space perceptive abilities
823
for old and new routes are significantly different as determined by Student’s t-test (P < 0.05).
824
ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration
825
of docosahexaenoic acid (100 mg/kg/day).
43
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
80
*
*
Page 44 of 60
*
Object perceptive ability (%)
70 60 50 familiar object
40
novel object 30 20 10 0
826
Normal
Control
ALA
DHA
827
Figure 3. Effects of alpha-linolenic acid on recognition memory in the novel object
828
recognition test in Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The object
829
perceptive abilities for familiar and novel objects are significantly different as determined by
830
student’s t-test (P < 0.05). ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day)
831
DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day).
44
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Control
ALA
DHA
70 60 50 a
40 30
1 day
Tertiary
Secondary
Primary
Tertiary
2 day
3 day
(D)
a
40 b 30 20 10 0 Control
ALA
a 60 50 40 30 20
b
b
b
ALA
DHA
10
Normal
4 day
50
Normal
70
0
a
a
(B)
Latency to reach platform (seconds)
60
Secondary
Primary
Secondary
0
Tertiary
10
Final
b b b
20
(C) Occupancy in target quadrant (%)
Normal
80
Primary
Latency to reach plarform (seconds)
(A)
Latency to reach platform (seconds)
Page 45 of 60
Control
35 NS 30 25 20 15 10 5 0
DHA
Normal
Control
ALA
DHA
832
Figure 4. (A) Effects of alpha-linolenic acid on escape latency to the platform in the Morris
833
water maze test in Aβ25-35-injected mice. (B) Effects of alpha-linolenic acid on latency to
834
reach the hidden platform in the Morris water maze test on the final test day in Aβ25-35-
835
injected mice. (C) Effects of alpha-linolenic acid on occupancy time of the target quadrant in
836
the Morris water maze test in Aβ25-35-injected mice. The percentage of time spent in the target
837
quadrant was calculated in the water maze test on the final test day. (D) Effects of alpha45
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
838
linolenic acid on latency to reach the exposed platform in the Morris water maze test in Aβ25-
839
35-injected
840
significantly different (P < 0.05) from each other. NS: No significance ALA: Oral
841
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
842
docosahexaenoic acid (100 mg/kg/day).
mice. Data represent mean ± SD (n=5).
a-b
Means with different letters are
46
ACS Paragon Plus Environment
Page 46 of 60
Page 47 of 60
Journal of Agricultural and Food Chemistry
Normal Control
ALA
DHA
BACE PS1 PS2 β-actin 843
Protein expression (fold of normal)
1.6
a a
1.4 1.2 d
c
a
b
a
c
a b
b c
1
Normal
0.8
Control ALA
0.6
DHA 0.4 0.2 0 BACE
PS1
PS2
844
Figure 5. Effects of alpha-linolenic acid on BACE, PS1 and PS2 protein expression levels
845
in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
846
letters are significantly different (P < 0.05) from each group. ALA: Oral administration of
847
alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid
848
(100 mg/kg/day).ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA:
849
Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading
850
control.
47
ACS Paragon Plus Environment
a-d
Means with different
Journal of Agricultural and Food Chemistry
Normal
Control
ALA
Page 48 of 60
DHA
sAPPα CTFβ (C99) CTFα (C83)
ADAM10 β-actin Protein expression (fold of normal)
1.4 1.2
a c
1
a b
a
b
d
c
0.8
Normal Control
0.6
ALA
0.4 c
0.2
DHA
b
d d
0 851
sAPPα
C83/C99
ADAM10
852
Figure 6. Effects of alpha-linolenic acid on sAPPα, CTFs, and ADAM10 protein expression
853
levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
854
different letters are significantly different (P < 0.05) from each group. ALA: Oral
855
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
856
docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control.
48
ACS Paragon Plus Environment
a-d
Means with
Page 49 of 60
Journal of Agricultural and Food Chemistry
Normal
Control
ALA
DHA
IDE NEP
Protein expression (fold of normal)
β-actin 1.4 1.2 1
a ab
b
a c
0.8
b
b
b
Normal Control ALA
0.6
DHA
0.4 0.2 0 IDE
NEP
857 858
Figure 7. Effects of alpha-linolenic acid on IDE and NEP protein expression levels in the
859
Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
860
are significantly different (P < 0.05) from each group. ALA: Oral administration of alpha-
861
linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100
862
mg/kg/day). β-actin was used as a loading control.
a-c
49
ACS Paragon Plus Environment
Means with different letters
Journal of Agricultural and Food Chemistry
Normal
Control
ALA
Page 50 of 60
DHA
RAGE LRP-1 β-actin
Protein epxressions (fold of normal)
1.4 1.2
a
a
NS
b 1
c Normal
0.8
Control
0.6
ALA
0.4
DHA
0.2 0 RAGE
LRP-1
863
864
Figure 8. Effects of alpha-linolenic acid on RAGE and LRP-1 protein expression levels in
865
the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3).
866
letters are significantly different (P < 0.05) from each group. NS: No significance. ALA: Oral
867
administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of
868
docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control.
50
ACS Paragon Plus Environment
a-c
Means with different
Page 51 of 60
869
Journal of Agricultural and Food Chemistry
TOC Graphics
870
51
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Figure 1. Behavioral experimental schedule for mice injected with Aβ25-35. 250x70mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 52 of 60
Page 53 of 60
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on the spatial perceptive ability in the T-maze test in Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The space perceptive abilities for old and new routes are significantly different as determined by Student’s t-test (P < 0.05). ALA: Oral administration of alphalinolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). 158x105mm (96 x 96 DPI)
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on recognition memory in the novel object recognition test in Aβ25-35-injected mice. Data are presented as mean ± SD (n=6). *The object perceptive abilities for familiar and novel objects are significantly different as determined by student’s t-test (P < 0.05). ALA: Oral administration of alphalinolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). 159x96mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 54 of 60
Page 55 of 60
Journal of Agricultural and Food Chemistry
(A) Effects of alpha-linolenic acid on escape latency to the platform in the Morris water maze test in Aβ25-35injected mice. (B) Effects of alpha-linolenic acid on latency to reach the hidden platform in the Morris water maze test on the final test day in Aβ25-35-injected mice. (C) Effects of alpha-linolenic acid on occupancy time of the target quadrant in the Morris water maze test in Aβ25-35-injected mice. The percentage of time spent in the target quadrant was calculated in the water maze test on the final test day. (D) Effects of alphalinolenic acid on latency to reach the exposed platform in the Morris water maze test in Aβ25-35-injected mice. Data represent mean ± SD (n=5). a-bMeans with different letters are significantly different (P < 0.05) from each other. NS: No significance ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). 175x165mm (96 x 96 DPI)
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on BACE, PS1 and PS2 protein expression levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3). a-dMeans with different letters are significantly different (P < 0.05) from each group. ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day).ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control. 127x147mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 56 of 60
Page 57 of 60
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on sAPPα, CTFs, and ADAM10 protein expression levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3). a-dMeans with different letters are significantly different (P < 0.05) from each group. ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control. 127x146mm (96 x 96 DPI)
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on IDE and NEP protein expression levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3). a-cMeans with different letters are significantly different (P < 0.05) from each group. ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control. 127x127mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 58 of 60
Page 59 of 60
Journal of Agricultural and Food Chemistry
Effects of alpha-linolenic acid on RAGE and LRP-1 protein expression levels in the Aβ25-35-injected mice brain. Data represent mean ± SD (n=3). a-cMeans with different letters are significantly different (P < 0.05) from each group. NS: No significance. ALA: Oral administration of alpha-linolenic acid (100 mg/kg/day) DHA: Oral administration of docosahexaenoic acid (100 mg/kg/day). β-actin was used as a loading control. 127x129mm (96 x 96 DPI)
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
TOC Graphics 254x190mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 60 of 60